Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

Amgen Inc (NASDAQ:AMGN)., a leading biopharmaceutical company with a market capitalization of $155 billion, is at a pivotal juncture as it navigates the competitive landscape of innovative ...

Analysts note that while the base business remains resilient, the focus has shifted to Amgen's pipeline and potential growth drivers. The integration of the Horizon franchise, bolstered by Tepezza ...

Robert Bradway, chairman and CEO said, “Robust growth in sales and earnings throughout 2024 reflects the momentum of our business. With strong ...

Amgen (NASDAQ: AMGN) will present at the 35th Annual Oppenheimer Healthcare Life Sciences Conference at 11:20 a.m. ET on Wednesday, Feb. 12, 2025. Narimon Honarpour, senior vice president of global ...

Analysts note that while the base business remains resilient, the focus has shifted to Amgen's pipeline and potential growth drivers. The integration of the Horizon franchise, bolstered by Tepezza's ...

Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial ...

Beyond MariTide, Amgen's pipeline includes other promising candidates such as rocatinlimab for atopic dermatitis, Uplizna for generalized myasthenia gravis, and fipaxalparant for idiopathic pulmonary ...